Key Highlights

  • NextPlat (NASDAQ:NXPL) changed hands at USD 6.30 on November 12, 2026, a 24% decline, with about 41,810 shares trading, roughly double the usual pace, and a Market Value near USD 17.09 million.
  • No company announcement surfaced for November 10 to 12, so the drop has no confirmed trigger, and the float is only about 1.5 million shares.
  • Second-quarter Revenue climbed about 21% from the prior quarter to roughly USD 11.9 million, gross Margin set a record near 40%, and the net loss narrowed to about USD 144,000.
  • Cash stood at about USD 11.9 million on June 30, 2026, and a Pensacola-area pharmacy purchase closed in October.

A Steep Slide in a Thin Market

NextPlat (NASDAQ:NXPL) operates on two fronts: PharmcoRx pharmacies across Florida, which handle 340B contract work, long-term care and prescription fulfilment, and an E-commerce and satellite device arm run by its UK Subsidiary Global Telesat Communications. On November 12 the stock dropped 24% to USD 6.30 on about 41,810 shares. That count was roughly double the usual pace, yet still modest in absolute terms. With only about 1.5 million shares in the float, even light selling can push the price a long way. Searches of November 10 to 12 turned up no press release, filing or contract announcement, and the third-quarter report is still ahead. The likeliest backdrop is repositioning before results in a stock with little trading, though that is an interpretation rather than a verified cause. The fall gives back much of the rally that followed the August second-quarter release, when shares jumped 20.86% in one session. Short-term traders in small floats can also magnify daily swings as they exit positions.

Operating Results Moved in the Right Direction

The most recent quarter was encouraging. Second-quarter revenue reached roughly USD 11.9 million, up from USD 9.9 million in the first quarter, a rise of about 21%. Gross margin set a record near 40%. The loss attributable to common holders narrowed to about USD 144,000, or USD 0.05 a share, compared with USD 1.1 million in the prior quarter. At June 30 the company reported roughly USD 11.9 million in cash, Working Capital of about USD 14.2 million and total liabilities near USD 12.2 million. In October it bought a Pensacola-area pharmacy for approximately USD 1.49 million in cash. That Business is profitable and carries no debt, with sales of about USD 5.6 million in 2025. A new Jacksonville pharmacy also opened, and specialty pharmacy accreditation arrived in July. Two revenue engines now run side by side, pharmacy growth and a smaller e-commerce unit, although healthcare produces the clear majority of sales.

Earnings Multiple and Catalysts

The screen lists trailing diluted losses of USD 3.70 a share, which is 19.42% better than a year earlier, though that figure mainly captures earlier losses rather than the recent quarter that came close to break-even. Full-year 2025 revenue totaled USD 54.3 million, so the roughly USD 17.09 million market value looks modest against sales, partly because turning revenue into steady profit has proved difficult. Attention now turns to the third-quarter release: revenue from newly acquired pharmacies, the direction of gross margin, movement toward profitability and any change in cash. A new e-commerce agreement signed in September might add support. With such a slim float, the shares will probably swing sharply in both directions until fresh results give investors a clearer signal.

Where Things Stand

NextPlat (NASDAQ:NXPL) dropped 24% to USD 6.30 on November 12, 2026 with no company news found, as sales in a stock with a float near 1.5 million shares hit ahead of third-quarter results. Revenue growth, a record gross margin and recent pharmacy purchases make a sound case, so the next report becomes the real test.